RankingsPricing
  1. US-listed companies
  2. ALNYLAM PHARMACEUTICALS, INC.
  3. Financials
  4. Research & development

ALNYLAM PHARMACEUTICALS, INC.ALNY

Market cap
$56.6B
P/E ratio
SummaryFinancials
Period EndResearch & development (Million USD)YoY (%)
Dec 31, 20241,126+12.13%
Dec 31, 20231,004+13.75%
Dec 31, 2022883+11.47%
Dec 31, 2021792+20.97%
Dec 31, 2020655-0.05%
Dec 31, 2019655+29.62%
Dec 31, 2018505+29.38%
Dec 31, 2017391+2.16%
Dec 31, 2016382+38.30%
Dec 31, 2015276+45.33%
Dec 31, 2014190+68.43%
Dec 31, 2013113+30.48%
Dec 31, 201287-12.82%
Dec 31, 201199-6.66%
Dec 31, 2010106

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)